![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/regentree-announces-additional-results-from-arise-3-and-after-pooling-data-from-three-phase-3-clinical-trials-using-rgn-259-for-the-treatment-of-dry-eye-301291451.html
https://www.prnewswire.com/news-releases/regentree-announces-efficacy-results-of-the-neurotrophic-keratopathy-phase-3-clinical-trial-with-rgn-259-301059114.html